Osteoporosis management in hematologic stem cell transplant recipients: Executive summary

Simple item page
dc.contributor.authorKendler, D.L.en_ZA
dc.contributor.authorBody, J.J.en_Za
dc.contributor.authorBrandi, M.L.en_ZA
dc.contributor.authorBroady, R.en_ZA
dc.contributor.authorCannata-Andia, J.en_ZA
dc.contributor.authorCannata-Ortiz, M.J.en_ZA
dc.contributor.authorEl Maghraoui, A.en_ZA
dc.contributor.authorGuglielmi, G.en_ZA
dc.contributor.authorHadji, P.en_ZA
dc.contributor.authorPierroz, D.D.en_ZA
dc.contributor.authorDe Villiers, T.J.en_ZA
dc.contributor.authorEbeling, P.R.en_ZA
dc.contributor.authorRizzolim, R.en_ZA
dc.date.accessioned2023-03-28T13:11:45Zen_ZA
dc.date.available2023-03-28T13:11:45Zen_ZA
dc.date.issued2021-06en_ZA
dc.descriptionCITATION: Kendler, D.L. et al. 2021. Osteoporosis management in hematologic stem cell transplant recipients: Executive summary. Journal of Bone Oncology 28(2021):100361. doi.10.1016/j.jbo.2021.100361en_ZA
dc.descriptionThe original publication is available at: elsevier.comen_ZA
dc.description.abstractBackground: Treatment advances have reduced the adverse events associated with hematopoietic stem cell transplant (HSCT) and led to an increased number of transplants performed. HSCT patients are living longer with concerns on long-term outcomes. Bone fragility and fracture are at the forefront for long-term morbidities post-HSCT. Results: In HSCT recipients, evidence has accumulated to support recommendations for more extensive monitoring of bone fragility and more appropriate administration of osteoporosis pharmacotherapies for patients at high risk of bone loss and/or fracture. Conclusion: This executive summary reports and summarizes the main recommendations published previously, including bone assessment, dietary and lifestyle recommendations and osteoporosis medication.en_ZA
dc.description.versionPublisher’s versionen_ZA
dc.format.extent4 pagesen_ZA
dc.identifier.citationKendler, D.L. et al. 2021. Osteoporosis management in hematologic stem cell transplant recipients: Executive summary. Journal of Bone Oncology 28(2021):100361. doi.10.1016/j.jbo.2021.100361en_ZA
dc.identifier.urihttp://hdl.handle.net/10019.1/126726en_ZA
dc.language.isoen_ZAen_ZA
dc.publisherElsevier GmbH.en_ZA
dc.rights.holderAuthors retain copyrighten_ZA
dc.subjectHematopoietic stem cellsen_ZA
dc.subjectBone marrow -- Transplantationen_ZA
dc.subjectStem cells -- Transplantationen_ZA
dc.subjectBones -- Diseasesen_ZA
dc.subjectFracturesen_ZA
dc.subjectUCTDen_ZA
dc.titleOsteoporosis management in hematologic stem cell transplant recipients: Executive summaryen_ZA
dc.typeArticleen_ZA
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
kendler_osteoporosis_2021.pdf
Size:
382.43 KB
Format:
Adobe Portable Document Format
Description:
download article
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Research Articles (Obstetrics and Gynaecology)